

March 30, 1965

William C. Janssen, M. D.
Director of Clinical Research
Lakeside Laboratories
1707 E. North Avenue
Milwaukee, Wisconsin 53201

Dear Dr. Janssen:

Thank you for your letter concerning Ditrán. I hope that the FDA will permit the continued study of this compound. We are most interested to continue our studies, and would appreciate an additional supply of Ditrán for investigational use as soon as you have filed the NDA.

With regard to your question as to the proposed limitation in distribution of Ditrán, I am in no position to make a specific suggestion. If there is some question in your mind, it would seem to me advisable to provide the drug initially to those investigators who have already had experience with the compound, as well as that larger group of investigators who are participating in the NIMH-PSC Early Clinical Drug Evaluation Program. This list of investigators can be obtained from Dr. Cole.

Thank you very much for your help.

Sincerely yours,

Max Fink, M. D.
Professor of Psychiatry

MF:kp

cc: Dr. Itil
Dr. Ulett